MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
25.30
+0.12
+0.48%
Pre Market: 25.20 -0.1 -0.40% 07:40 08/13 EDT
OPEN
25.49
PREV CLOSE
25.18
HIGH
25.65
LOW
24.89
VOLUME
36
TURNOVER
0
52 WEEK HIGH
40.65
52 WEEK LOW
9.96
MARKET CAP
1.51B
P/E (TTM)
-10.5729
1D
5D
1M
3M
1Y
5Y
1D
John Newman Maintains Buy Rating on Tyra with Unchanged $50 Price Target, Citing Dabogratinib’s Strong Growth Potential and Safety Profile in Achondroplasia
TipRanks · 1d ago
Tyra Biosciences price target lowered to $39 from $42 at BofA
TipRanks · 1d ago
Weekly Report: what happened at TYRA last week (0803-0807)?
Weekly Report · 3d ago
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet
Seeking Alpha · 3d ago
Tyra Biosciences (TYRA) Reports Q2 Results, Is The Pipeline Potential Already Priced In?
Simply Wall St · 08/05 20:25
Tyra Biosciences price target lowered to $42 from $44 at Jefferies
TipRanks · 08/05 19:16
Tyra Biosciences delayed cancer data by one month, says JonesResearch
TipRanks · 08/05 16:40
Tyra Biosciences falls 20% after pushing data readout to September from August
TipRanks · 08/05 16:40
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.